Defendants in ITC case involving Botox warn of possible precedent-setting ruling

Supporters of the defendant in a U.S. International Trade Commission case, brought by the makers of Botox, are raising concerns about a potentially precedent-setting ruling they say could transform the ITC into an adjudicator of foreign disputes and undermine its mission to protect domestic interests. The U.S. manufacturer of Botox, Allergan, and Medytox, the Korean manufacturer of a similar product, last year filed a joint complaint – under Section 337 of the Tariff Act of 1930 – against Daewoong, a...